News & Events

View the various news of Celemics

News & Events

  • [AASV2023] Booth Information (Gaylord Rockies Resort & Convention Center) (2/10/2023) Posted in: EVENT 6-7 March 2023
  • [MEDLAB2023] Booth Information (Dubai World Trade Centre / 6-9 February 2023) (12/13/2022) Posted in: EVENT
  • [FoG2023] Booth Information (Business Design Centre, London / 25-26 January 2023) (12/8/2022) Posted in: EVENT
  • [FCS 2022] Booth Information (LKCMedicine, Singapore / 7-9 November 2022) (10/26/2022) Posted in: EVENT
  • [ASHG 2022] Booth Information (Los Angeles Convention Center / 26-28 October 2022) (9/22/2022) Posted in: EVENT
  • ESHG 2022 Booth Information (Vienna, Austria / 11-14 June 2022) (6/7/2022) Posted in: EVENT
  • MEDLAB 2022 Booth Information (Dubai World Trade Centre / 24-27 January 2022) (1/6/2022) Posted in: EVENT
  • Celemics signs an agreement to supply BTSeq™ to Sangon Biotech Co., Ltd., a Chinese genetic analysis company (10/29/2021) Posted in: NEWS

    Digital Journal Daily Herald GenomeWeb WRDECOAST TV

    Celemics signs an agreement to supply BTSeq™ to Sangon Biotech Co., Ltd., a Chinese genetic analysis company

    – Successive global expansion following the signing of a supply contract with Tsingke in July
    – Wide range of business expectations, such as expansion of high value-added applications and replacement of Sanger sequencing

    October 28, 2021, Seoul, Korea: Celemics, Inc. (CEO Young-hoon Lee, Hyo-ki Kim /, an NGS-based sequencing solution and
    bioinformatics tech company, announced on the 28th that it has signed an annual supply agreement of BTSeq™ (Barcode-Tagged Sequencing)
    with Sangon Biotech Co., Ltd., located in Shanghai, China.

    Sangon, which successfully signed a supply agreement this time, operates 12 subsidiaries throughout China, including in Nanjing and Qingdao,
    with the main focus on its headquarters in Shanghai. With annual sales of 164 billion KRW ($ 140.3 million) in 2020, it is considered one of
    the most important Sanger Sequencing companies along with Tsingke and BGI. After signing the first global BTSeq™ supply agreement with
    Tsingke in July, Celemics signed the second global supply agreement in three months, securing two top Chinese genetic analysis companies as customers,
    and solidified its position in China’s NGS market.

    In this annual supply agreement, the minimum supply quantity is 100,000 reactions (rxn), and provides both Celemics’s BTSeq™ kits and bioinformatics software
    to various service fields operated by Sangon. It was arranged in a short period as it was determined that the technical skills and commercial value of BTSeq™ were
    in line with the future strategic direction of Sangon to expand with a high value-added business such as NGS. A company official explained thatas BTSeq™ can be applied to
    various application fields, it can also be used to not only develop high value-added NGS application developments, but also replace Sanger sequencing in the existing flagship businesses.

    Sangon CEO Wang Gye-song (王啓松) said, “After we set the business direction by expanding high value-added applications, we expect that our new strategy will gain momentum
    through BTSeq™’s wide scalability.”

    Young-hoon Lee, co-CEO of Celemics, said, “Even when the schedule was delayed due to the coronavirus pandemic, the fact that the contract with Tsingke was executed through
    extensive verification procedures serves as a good reference and is receiving a lot of attention from customers. While promoting BTSeq™’s overseas expansion, we have prioritized
    the Chinese NGS market, which has the highest global growth potential. I’m glad we had great results. We will do our best to secure our position in other Asian, and Middle Eastern,
    and European countries as well.”


  • [Medica 2021] Celemics Booth Information (10/14/2021) Posted in: EVENT
  • [Promotion] G-Mendeliome Clinical Exome Sequencing (CES) Panel (10/13/2021) Posted in: EVENT
  • Celemics signs a supply agreement for BTSeq™ solution with Chinese Sanger sequencing service company (7/14/2021) Posted in: NEWS

    Celemics signs a supply agreement for BTSeq™ solution with Chinese Sanger sequencing service company

    – Celemics enters the Chinese DNA Sequencing market since its establishment
    – NGS-based BTSeq™ solution allows for highly accurate DNA sequencing with significantly reduced cost and time
    – The agreement scale is equivalent to 87% in celemics’ annual revenue

    July.14.2021, Seoul, Korea: Celemics, Inc.(, an NGS-based sequencing solution and bioinformatics company, Co-CEO Young-hoon Lee and Hyo-ki Kim announced on July 14th
    that Celemics has signed an annual supply agreement to provide 4.5 billion KRW ($3.9 million) worth BTSeq™ solution with Tsingke Biological Technology Co., Ltd. (Tsingke), a professional Beijing-based
    Sanger sequencing and gene synthesis service company.

    The agreement scale is equivalent to 87% of Celemics’ annual sales of 5.2 billion KRW ($4.5 million) in 2020, which is the largest single contract that Celemics has signed since expanding to the
    global market in 2017. Celemics will provide BTSeq™ reagents and analysis software, a proprietary genomics analysis platform, in China to Tsingke.

    Celemics’ technology supplied to Tsingke with this agreement is BTSeq™ (Barcode Tagged Sequencing) which utilizes NGS technology and Celemics’ proprietary sample preparation reagents and
    de novo assembly bioinformatics software. BTSeq™ solution allows for highly accurate DNA sequencing with significantly reduced cost and time. With the conventional method, Sanger sequencing,
    the sequencing of a few kb to 20 kb-long DNA takes several days to a few weeks and requires multiple sequencing runs and primer syntheses with high cost. BTSeq™ overcomes these challenges and
    enables accurate sequencing of 20 kb-long or longer DNA within 24 hours. With Celemics proprietary reagents and bioinformatics, the cost for NGS-based sequencing and the time required for
    analysis is significantly reduced.

    Tsingke, Celemics’ Chinese partner for the Chinese genome analysis market, is a professional DNA synthesis and sequencing company established in 2004. Tsingke has 19 subsidiaries in China,
    including Beijing, Shanghai and Guangzhou and is a large-scale business proceeding with about 15 million DNA synthesis and sequencing cases annually. Tsingke conducted thorough validation with
    various samples in its affiliated companies in Nanjing, Tianjin, etc. to check the BTSeq™ performance and purchased large volume of reagent and analysis software for beta operation.
    After about a year of the rigorous validation period, Tsingke decided to introduce Celemics’ BTSeq™ solution.

    “We expect to secure exclusive competitiveness in DNA synthesis and sequencing service with the new Celemics’ sequencing technology, BTSeq™, and will pioneer diverse application markets with Celemics.”
    ‘Tsingke CEO Ma Shijin’

    “Celemics is delighted to enter the Chinese NGS market through scrupulous examinations, which reassure the competitiveness of BTSeq™. Celemics will take this contract as a stepping stone to expand
    our contribution for researchers and companies in the fast-growing Chinese DNA sequencing market with 1.4 billion population.”
    ‘Celemics Co-Founder & CEO Hyoki Kim’

    Meanwhile, Celemics has been continuously and successfully preparing to expand to the global market. Celemics has recently completed designating distributors in countries such as Spain, Portugal,
    United Arab Emirate (UAE) and Japan and concluded partnership arrangements with distinguished international companies.


  • Celemics, South Dakota State University, announce partnership for the development of Hybridization NGS-based Multiple Swine Pathogen Co-Detection Panel (7/7/2021) Posted in: NEWS

    Genomeweb EINPRESSWIRE

    Celemics, South Dakota State University, announce partnership for the development of Hybridization NGS-based Multiple Swine Pathogen Co-Detection Panel.

    – The proposed methods are seen as a revolutionary step towards preventing swine respiratory diseases

    July 07, 2021, Seoul, Korea: Celemics, Inc.( has partnered with South Dakota State University’s Animal Disease Research and Diagnostic Laboratory (ADRDL) to create the first-ever hybridization-based
    next generation sequencing (NGS) kit to detect viral and bacterial swine respiratory pathogens.

    Most current diagnostic technologies are based on culture or qPCR. These widely used methods come with a great amount of limitations in terms of detecting a wide range of pathogens. The new and proposed breakthrough technique
    can make it possible to detect several viral and bacterial pathogens at once.

    Celemics Inc. is known for its innovative and ground-breaking research. It was the need of the hour to alter the paradigm of medicine for swine respiratory diagnosis and treatment. It is hoped that their much-welcomed partnership with
    the esteemed South Dakota State University will bring revolutionary methods for early detection and cure to the industry.
    Until this point in time, the genetic characterization, including whole genome sequence information for viral pathogens and multi-locus sequencing typing (MLST) analysis for bacterial pathogens, is attained through pathogen detection methods.
    This joint venture of research between the two reputed names has given them hope for improved overall herd health outcomes. The technology aims to overcome the shortfalls of modern diagnostics by enabling highly multiplexed detection
    and sequence characterization.
    Not only would this be more efficient but considerably cost-effective in comparison to the existing practices.

    We spoke to Mr. Benjamin Hause, Assistant Professor in the Department of Veterinary and Biomedical Sciences, about this promising prospect:
    “We are pleased to partner with Celemics on developing and bringing this exciting new technology to the swine industry,” ‘Celemics’ hybridization panel represents a large leap forward in our ability to detect and concurrently
    genetically characterize swine pathogens.
    While we focus on the most significant pathogens such as porcine reproductive and respiratory syndrome virus and influenza A virus, clinical disease is often the end result of co-infections with a number of viruses and bacteria.
    Celemics’ technology will enable comprehensive pathogen screening that will allow better herd management and improved swine health.”
    The technology aims to overcome the shortfalls of modern diagnostics by enabling highly multiplexed detection and sequence characterization. Not only would this be more efficient but considerably cost-effective in comparison to the existing practices.

    The kit results from years of remarkable research and comprises more than 50 different viral and bacterial swine pathogens. All of these sequences have been carefully chosen based on the study of patterns that are relevant to swine health
    and include domestically critical species such as the porcine reproductive and respiratory syndrome virus (PRRSV) and influenza A virus, along with foreign viruses such as African swine fever virus (ASFV) and foot and mouth disease virus.
    “With this new partnership, we hope to provide clinicians, veterinarians, and livestock breeders with a powerful, comprehensive tool for swine disease detection and prevention,” said co-CEO and founder of Celemics, Dr. Hyoki Kim.

    Through the advantages of hybridization NGS, we hope to provide a kit capable of revolutionizing clinical research and diagnostics and hope to effectively combat future swine disease epidemics.


  • [Webinar] Celemics X Strand Life Science Fast Automated Cancer Variant Prioritization & Reporting using stranomics (7/2/2021) Posted in: EVENT
  • Celemics, Strand Life Sciences Partner on Integrated Platform for NGS Analysis (6/15/2021) Posted in: NEWS

    GenomeWeb Microbioz India BioSpectrumasia IndiaMedtoday

    Celemics Partner with Strand Life Science and their StrandOmics Analysis Platform

    – Strand Life Science will provide their StrandOmics analysis platform in conjunction with Celemics bioinformatic pipeline, including assay-specific variant filters with a complete sample-to-report solution.
    – This partnership will help to provide guaranteed clinical-grade data compliance for customers

    June 09, 2021, Seoul Korea: Celemics( co-founder and CEO Dr. Hyoki Kim announced a partnership with Strand Life Sciences, a leading precision medicine informatics company,
    to develop a bioinformatics solution capable of providing users with an accelerated means of producing high-quality, in-class clinical genomics reports and enabling a complete sample-to-answer solution,
    including assay-specific variant filters.

    Under the agreement, Strand Life Science will integrate the Celemics bioinformatics pipeline into the StrandOmics tertiary analysis platform to enable Celemics with a complete sample-to-report solution.
    Leveraging the StrandOmics platform, Celemics plans to serve an expanding global market with clinical-grade data compliance and guaranteed data residency for customers in Europe, Asia, and beyond.

    Celemics Co-Founder and CEO Hyoki Kim said, “We are excited about this new partnership with Strand Life Sciences. Their expertise in the engineering of NGS systems and long track record with the
    instrument and diagnostic companies will be valuable in accelerating our path to market integration.”
    Also, Stand Life Sciences CEO Dr. Ramesh Hariharan said, “With our unique track record of running NGS labs as well as interpretation support for genetic tests, we are excited to partner with Celemics
    to help bring their cancer; inherited cancer, and rare disease panels to the market.”

    Founded in 2000 by academics from the Indian Institute of Science, Strand Life Sciences is a specialized genomics solutions company offering bioinformatics, knowledge-based curation development,
    software, assay design, and clinical research services globally, and also operates a diagnostics reference lab with a focus on genomics and oncology in India.
    Celemics is a biotech company developing and supplying critical enabling solutions in genomics, antibody discovery, medicine, biopharma, microbiome, synthetic biology, and AgBio.
    Founded in 2010, Celemics has focused in the last several years on providing target enrichment panels to Europe and Asia for various applications, including oncology, inherited disease,
    and genetic marker discovery.


  • Breakthrough test kit identifies 39 virus strains including Covid-19 mutations (1/6/2021) Posted in: NEWS


    Diagnostics World



    Celemics Launches Comprehensive Respiratory Virus (CRV) Panel for accurate identification and sequencing of whole respiratory virus genomes

    – A NGS approach to detect 39 strains of 9 common human respiratory viruses including SARS-CoV-2, several other coronaviruses, influenzas, rhinoviruses, and respiratory syncytial virus 

    – Offers fast and reliable multiplexed detection of respiratory pathogens in a single reaction 


    Celemics Inc., a company innovating DNAbased material through novel sequencing technology, announced the launch of its Comprehensive Respiratory Virus (CRV) Panel,
    an optimal Research Use Only (RUO) NGS target enrichment solution covering 9 common human respiratory viruses including SARS-CoV-2. 


    The Celemics CRV Panel includes 39 strains of the 9 most prevalent respiratory viruses including coronaviruses (CoV), influenza virus, adenovirus, bocavirus (hBoV), enterovirus,
    metapneumovirus, parainfluenza virus (hPIV), human rhinovirus (HRV), and respiratory syncytial virus (RSV). Unlike common RT-PCR assays, which detect only one pathogen at a time,
    the NGS-based Celemics CRV Panel is designed to identify, detect, and sequence each pathogen and any present mutations in a single reaction. 


    Celemics has engineered the Celemics CRV Panel to provide flexible and reliable performance. The Celemics CRV Panel shows more than 100X coverage for over 99% of the viral genome,
    offers a hybridization time four times faster than the current standard, and it detects concentrations as low as 100 viral copies per virus, enabling researchers to analyze nasopharyngeal samples,
    which commonly do not yield viral loads of sufficient quantity and quality needed for NGS applications. 


    The Celemics CRV Panel is bundled with a non-cloud based standalone bioinformatics software that enables a complete workflow beginning with library preparation and resulting
    in publication-ready results that are not subject to General Data Protection Regulations (GDPR).


    The Celemics CRV Panel is available for access in the United States, Europe, Latin America, Middle East, Singapore, Malaysia, and Thailand via Celemics’ certified retailers.